A novel assessment of nefazodone-induced hERG inhibition by electrophysiological and stereochemical method

Toxicology and Applied Pharmacology

Volumn 274, Issue 3, 2014, Pages 361-371

  Shin, Dae Seop ^a   Park, Myoung Joo ^a   Lee, Hyang Ae ^a   Lee, Joo Yun ^a   Chung, Hee Chung ^a   Yoo, Dae Seok ^a   Chae, Chong Hak ^a   Park, Sang Joon ^b   Kim, Ki Suk ^a   Bae, Myung Ae ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

Cardiotoxicity; HEK 293 cells; HERG; Nefazodone; Patch clamp

Indexed keywords

ALANINE; AMINE; NEFAZODONE; POTASSIUM CHANNEL HERG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOMATED PATCH CLAMP; CARDIOTOXICITY; CONTROLLED STUDY; DEPOLARIZATION; DRUG DEVELOPMENT; DRUG TOXICITY; ELECTROPHYSIOLOGICAL PROCEDURES; HUMAN; HUMAN CELL; IC 50; NONHUMAN; REPOLARIZATION; STEADY STATE; STEREOCHEMISTRY; VOLTAGE CLAMP TECHNIQUE;

CARDIOTOXICITY; HEK-293 CELLS; HERG; NEFAZODONE; PATCH CLAMP;

BINDING SITES; CARDIOTOXINS; COMPUTER SIMULATION; ELECTROPHYSIOLOGICAL PHENOMENA; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; PATCH-CLAMP TECHNIQUES; PROTEIN CONFORMATION; STEREOISOMERISM; TRIAZOLES;

EID: 84892457325     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.12.012     Document Type: Article

References (76)

1. Arrigoni C., Crivori P. Assessment of QT liabilities in drug development. Cell Biol. Toxicol. 2007, 23:1-13.
2. Bains W., Basman A., White C. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol. Biol. 2004, 86:205-233.
3. Broadhurst P., Nathan A.W. Cardiac arrest in a young woman with the long QT syndrome and concomitant astemizole ingestion. Br. Heart J. 1993, 70:469-470.
4. Cavalli A., Poluzzi E., De Ponti F., Recanatini M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. 2002, 45:3844-3853.
5. Chiang C.E., Roden D.M. The long QT syndromes: genetic basis and clinical implications. J. Am. Coll. Cardiol. 2000, 36:1-12.
6. Choi S. Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ 2003, 169:1187.
7. Crane G.E. Cardiac toxicity and psychotropic drugs. Dis. Nerv. Syst. 1970, 31:534-539.
8. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80:795-803.
9. Davidson J.R., Weisler R.H., Malik M.L., Connor K.M. Treatment of posttraumatic stress disorder with nefazodone. Int. Clin. Psychopharmacol. 1998, 13:111-113.
10. Davis R., Whittington R., Bryson H.M. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997, 53:608-636.
11. De Ponti F., Poluzzi E., Cavalli A., Recanatini M., Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 2002, 25:263-286.
12. Deacon M., Singleton D., Szalkai N., Pasieczny R., Peacock C., Price D., Boyd J., Boyd H., Steidl-Nichols J.V., Williams C. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade. J. Pharmacol. Toxicol. Methods 2007, 55:238-247.
13. del Camino D., Holmgren M., Liu Y., Yellen G. Blocker protection in the pore of a voltage-gated K+channel and its structural implications. Nature 2000, 403:321-325.
14. DeSanty K.P., Amabile C.M. Antidepressant-induced liver injury. Ann. Pharmacother. 2007, 41:1201-1211.
15. Dong Q., Fu X.X., Du L.L., Zhao N., Xia C.K., Yu K.W., Cheng L.X., Du Y.M. Blocking of the human ether-a-go-go-related gene channel by imatinib mesylate. Biol. Pharm. Bull. 2013, 36:268-275.
16. Drolet B., Vincent F., Rail J., Chahine M., Deschenes D., Nadeau S., Khalifa M., Hamelin B.A., Turgeon J. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J. Pharmacol. Exp. Ther. 1999, 288:1261-1268.
17. Eison A.S., Eison M.S., Torrente J.R., Wright R.N., Yocca F.D. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol. Bull. 1990, 26:311-315.
18. Farid R., Day T., Friesner R.A., Pearlstein R.A. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg. Med. Chem. 2006, 14:3160-3173.
19. Fernandez D., Ghanta A., Kauffman G.W., Sanguinetti M.C. Physicochemical features of the HERG channel drug binding site. J. Biol. Chem. 2004, 279:10120-10127.
20. Ferrer-Villada T., Navarro-Polanco R.A., Rodriguez-Menchaca A.A., Benavides-Haro D.E., Sanchez-Chapula J.A. Inhibition of cardiac HERG potassium channels by antidepressant maprotiline. Eur. J. Pharmacol. 2006, 531:1-8.
21. Goldberg J.F. A preliminary open trial of nefazodone added to mood stabilizers for bipolar depression. J. Affect. Disord. 2013, 144:176-178.
22. Greene D.S., Barbhaiya R.H. Clinical pharmacokinetics of nefazodone. Clin. Pharmacokinet. 1997, 33:260-275.
23. Gu D.F., Li X.L., Qi Z.P., Shi S.S., Hu M.Q., Liu D.M., She C.B., Lv Y.J., Li B.X., Yang B.F. Blockade of HERG K+channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells. Naunyn Schmiedeberg's Arch. Pharmacol. 2009, 380:143-151.
24. Hondeghem L.M., Dujardin K., Hoffmann P., Dumotier B., De Clerck F. Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. J. Cardiovasc. Pharmacol. 2011, 57:589-597.
25. Hosaka Y., Iwata M., Kamiya N., Yamada M., Kinoshita K., Fukunishi Y., Tsujimae K., Hibino H., Aizawa Y., Inanobe A., Nakamura H., Kurachi Y. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant. Channels 2007, 1:198-208.
26. Isbister G.K., Hackett L.P. Nefazodone poisoning: toxicokinetics and toxicodynamics using continuous data collection. J. Toxicol. Clin. Toxicol. 2003, 41:167-173.
27. Kamiya K., Mitcheson J.S., Yasui K., Kodama I., Sanguinetti M.C. Open channel block of HERG K(+) channels by vesnarinone. Mol. Pharmacol. 2001, 60:244-253.
28. Kamiya K., Niwa R., Mitcheson J.S., Sanguinetti M.C. Molecular determinants of HERG channel block. Mol. Pharmacol. 2006, 69:1709-1716.
29. Keating M.T., Sanguinetti M.C. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001, 104:569-580.
30. Kim K.S., Kim E.J., Lee H.A., Park S.J. Effect of sibutramine HCl on cardiac hERG K+channel. Mol. Cell. Biochem. 2009, 320:125-131.
31. Langheinrich U., Vacun G., Wagner T. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol. Appl. Pharmacol. 2003, 193:370-382.
32. Lathers C.M., Lipka L.J. Cardiac arrhythmia, sudden death, and psychoactive agents. J. Clin. Pharmacol. 1987, 27:1-14.
33. Lees-Miller J.P., Duan Y., Teng G.Q., Duff H.J. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol. 2000, 57:367-374.
34. Leonard C.E., Bilker W.B., Newcomb C., Kimmel S.E., Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol. Drug Saf. 2011, 20:903-913.
35. Long Y., Lin Z., Xia M., Zheng W., Li Z. Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride. Toxicol. Appl. Pharmacol. 2013, 267:155-166.
36. Milnes J.T., Crociani O., Arcangeli A., Hancox J.C., Witchel H.J. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol. 2003, 139:887-898.
37. Mitcheson J.S. hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem. Res. Toxicol. 2008, 21:1005-1010.
38. Mitcheson J.S., Perry M.D. Molecular determinants of high-affinity drug binding to HERG channels. Curr. Opin. Drug Discov. Dev. 2003, 6:667-674.
39. Mitcheson J.S., Chen J., Lin M., Culberson C., Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12329-12333.
40. Park S.J., Kim K.S., Kim E.J. Blockade of HERG K+channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656. J. Appl. Toxicol. 2008, 28:104-111.
41. Park M.J., Lee K.R., Shin D.S., Chun H.S., Kim C.H., Ahn S.H., Bae M.A. Predicted drug-induced bradycardia related cardio toxicity using a zebrafish in vivo model is highly correlated with results from in vitro tests. Toxicol. Lett. 2013, 216:9-15.
42. Patmore L., Fraser S., Mair D., Templeton A. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur. J. Pharmacol. 2000, 406:449-452.
43. Pearlstein R., Vaz R., Rampe D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+channel. A model for bad behavior. J. Med. Chem. 2003, 46:2017-2022.
44. Pearlstein R.A., Vaz R.J., Kang J., Chen X.L., Preobrazhenskaya M., Shchekotikhin A.E., Korolev A.M., Lysenkova L.N., Miroshnikova O.V., Hendrix J., Rampe D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 2003, 13:1829-1835.
45. Perry M., de Groot M.J., Helliwell R., Leishman D., Tristani-Firouzi M., Sanguinetti M.C., Mitcheson J. Structural determinants of HERG channel block by clofilium and ibutilide. Mol. Pharmacol. 2004, 66:240-249.
46. Picard S., Lacroix P. QT interval prolongation and cardiac risk assessment for novel drugs. Curr. Opin. Investig. Drugs 2003, 4:303-308.
47. Piper D.R., Duff S.R., Eliason H.C., Frazee W.J., Frey E.A., Fuerstenau-Sharp M., Jachec C., Marks B.D., Pollok B.A., Shekhani M.S., Thompson D.V., Whitney P., Vogel K.W., Hess S.D. Development of the predictor HERG fluorescence polarization assay using a membrane protein enrichment approach. Assay Drug Dev. Technol. 2008, 6:213-223.
48. Rasimas J.J., Burkhart K.K. Cardiac conduction disturbances after an overdose of nefazodone and gabapentin. Am. J. Emerg. Med. 2006, 24:886-888.
49. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
50. Ridley J.M., Dooley P.C., Milnes J.T., Witchel H.J., Hancox J.C. Lidoflazine is a high affinity blocker of the HERG K(+)channel. J. Mol. Cell. Cardiol. 2004, 36:701-705.
51. Roche O., Trube G., Zuegge J., Pflimlin P., Alanine A., Schneider G. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem 2002, 3:455-459.
52. Roden D.M., Lazzara R., Rosen M., Schwartz P.J., Towbin J., Vincent G.M. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996, 94:1996-2012.
53. Rodriguez B., Burrage K., Gavaghan D., Grau V., Kohl P., Noble D. The systems biology approach to drug development: application to toxicity assessment of cardiac drugs. Clin. Pharmacol. Ther. 2010, 88:130-134.
54. Sanchez-Chapula J.A., Navarro-Polanco R.A., Culberson C., Chen J., Sanguinetti M.C. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+channel block. J. Biol. Chem. 2002, 277:23587-23595.
55. Sanchez-Chapula J.A., Ferrer T., Navarro-Polanco R.A., Sanguinetti M.C. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol. Pharmacol. 2003, 63:1051-1058.
56. Sanguinetti M.C. HERG1 channelopathies. Pflugers Arch. 2010, 460:265-276.
57. Sanguinetti M.C., Jurkiewicz N.K. Two components of cardiac delayed rectifier K+current. Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 1990, 96:195-215.
58. Scholz E.P., Zitron E., Kiesecker C., Lueck S., Kathofer S., Thomas D., Weretka S., Peth S., Kreye V.A., Schoels W., Katus H.A., Kiehn J., Karle C.A. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedeberg's Arch. Pharmacol. 2003, 368:404-414.
59. Semama D.S., Bernardini S., Louf S., Laurent-Atthalin B., Gouyon J.B. Effects of cisapride on QTc interval in term neonates. Arch. Dis. Child. Fetal Neonatal Ed. 2001, 84:F44-F46.
60. Sharpe R.H., Voris J.C. Nefazodone in the treatment of patients with post-traumatic stress disorder. Expert. Rev. Neurother. 2002, 2:617-623.
61. Shen J., Kennedy S.H., Levitan R.D., Kayumov L., Shapiro C.M. The effects of nefazodone on women with seasonal affective disorder: clinical and polysomnographic analyses. J. Psychiatry Neurosci. 2005, 30:11-16.
62. Siddiqui M.A., Khan I.A. Nefazodone-associated torsade de pointes. Int. J. Cardiol. 2004, 93:85-86.
63. Siebrands C.C., Schmitt N., Friederich P. Local anesthetic interaction with human ether-a-go-go-related gene (HERG) channels: role of aromatic amino acids Y652 and F656. Anesthesiology 2005, 103:102-112.
64. Smith P.L., Baukrowitz T., Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996, 379:833-836.
65. Spector P.S., Curran M.E., Zou A., Keating M.T., Sanguinetti M.C. Fast inactivation causes rectification of the IKr channel. J. Gen. Physiol. 1996, 107:611-619.
66. Su Z., Martin R., Cox B.F., Gintant G. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+channel. J. Mol. Cell. Cardiol. 2004, 36:151-160.
67. Su Z., Chen J., Martin R.L., McDermott J.S., Cox B.F., Gopalakrishnan M., Gintant G.A. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem. Pharmacol. 2006, 71:278-286.
68. Tamargo J., Caballero R., Gomez R., Valenzuela C., Delpon E. Pharmacology of cardiac potassium channels. Cardiovasc. Res. 2004, 62:9-33.
69. Tao H., Santa Ana D., Guia A., Huang M., Ligutti J., Walker G., Sithiphong K., Chan F., Guoliang T., Zozulya Z., Saya S., Phimmachack R., Sie C., Yuan J., Wu L., Xu J., Ghetti A. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev. Technol. 2004, 2:497-506.
70. Taylor D.P., Carter R.B., Eison A.S., Mullins U.L., Smith H.L., Torrente J.R., Wright R.N., Yocca F.D. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J. Clin. Psychiatry 1995, 56(Suppl. 6):3-11.
71. Trudeau M.C., Warmke J.W., Ganetzky B., Robertson G.A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995, 269:92-95.
72. Vandenberg J.I., Walker B.D., Campbell T.J. HERG K+channels: friend and foe. Trends Pharmacol. Sci. 2001, 22:240-246.
73. Walker B.D., Singleton C.B., Bursill J.A., Wyse K.R., Valenzuela S.M., Qiu M.R., Breit S.N., Campbell T.J. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br. J. Pharmacol. 1999, 128:444-450.
74. Witchel H.J., Hancox J.C. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current. Clin. Exp. Pharmacol. Physiol. 2000, 27:753-766.
75. Zhao J., Lian Y., Lu C., Jing L., Yuan H., Peng S. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels. J. Ethnopharmacol. 2012, 141:685-691.
76. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., January C.T. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J. 1998, 74:230-241.